Welcome to our dedicated page for Cormedix news (Ticker: CRMD), a resource for investors and traders seeking the latest updates and insights on Cormedix stock.
CorMedix Inc. (Nasdaq: CRMD), also referred to as CorMedix Therapeutics in recent announcements, generates frequent news as a biopharmaceutical company focused on therapeutic products for life-threatening conditions and diseases. Its updates cover commercial performance, clinical development, corporate transactions, and capital markets activity, giving investors and healthcare professionals multiple angles from which to follow the company.
News about CorMedix often highlights the commercial rollout and utilization of DefenCath, an antimicrobial catheter lock solution approved to reduce catheter-related bloodstream infections in certain adult hemodialysis patients using central venous catheters. Press releases have discussed real-world evidence studies with outpatient dialysis organizations, including reductions in infection rates and hospitalizations, as well as recognition such as an Innovative Technology designation from Vizient.
Following its acquisition of Melinta Therapeutics LLC, CorMedix news also covers a broader anti-infective portfolio, including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, along with TOPROL-XL. Investors can expect updates on sales trends, integration progress, and synergy capture related to this transaction. Clinical news includes milestones in the Phase III ReSPECT study of REZZAYO for prophylaxis of invasive fungal disease in allogeneic blood and marrow transplant patients, as well as studies of DefenCath in Total Parenteral Nutrition and pediatric hemodialysis populations.
Regulatory and financial announcements are another important category, such as quarterly and annual results, revenue guidance changes, equity and debt financings, and SEC filings describing material events. Strategic items, including CorMedix’s investment in Talphera and associated board representation and negotiation rights, also appear in the company’s news flow. For investors tracking CRMD, this news page provides a centralized view of earnings releases, clinical data readouts, product designations, conference presentations, and governance updates.
Joseph Todisco appointed as CEO of CorMedix effective May 16, 2022. With over 20 years in the specialty pharmaceuticals industry, Todisco aims to advance the company’s lead product, DefenCath, which has received FDA Fast Track and QIDP designations. He previously held senior roles at Amneal Pharmaceuticals, contributing to significant revenue growth. The company plans to pursue a commercial launch and expand its product pipeline. Interim CEO Dr. Matt David highlighted ongoing improvements following a Complete Response Letter from the FDA regarding manufacturing deficiencies.
CorMedix Inc. (Nasdaq: CRMD) has resubmitted its New Drug Application (NDA) for DefenCath to the FDA, addressing previously noted deficiencies in a Complete Response Letter. DefenCath is designed to reduce catheter-related bloodstream infections in patients undergoing chronic hemodialysis. The company's third-party manufacturer has also responded to necessary changes identified by the FDA. The FDA will review the resubmission for completeness within 30 days, and a preapproval inspection may be required.
CorMedix Inc. (Nasdaq: CRMD) announced participation in multiple upcoming investor conferences in January 2022. Key events include:
- LifeSci Partners – January 5-7
- H.C. Wainwright Bioconnect Virtual Conference – January 10-13
- Biotech Showcase Virtual Conference – January 10-12
CorMedix focuses on developing therapeutic products, notably DefenCath™, for preventing life-threatening infections related to central venous catheters in hemodialysis patients. The FDA has designated DefenCath as Fast Track and QIDP, offering extended marketing exclusivity upon NDA approval.
CorMedix Inc. (Nasdaq: CRMD) reported its third quarter 2021 financial results, announcing a net loss of $8.6 million or $0.22 per share, compared to a loss of $6.6 million in Q3 2020. The increase in losses was attributed to a 30% rise in operating expenses, primarily due to heightened manufacturing costs for DefenCath. Despite challenges, manufacturing activities have resumed, and the company aims to resubmit its NDA. With $72 million in cash, CorMedix believes it can fund operations through 2022. A conference call is scheduled for November 9, 2021 to further discuss developments.
CorMedix Inc. (CRMD) announced it will report its Q3 financial results on November 9, 2021, following the market close. The company specializes in developing therapeutic products for infectious and inflammatory diseases, with a focus on its lead product, DefenCath. This product aims to prevent bloodstream infections related to central venous catheters in chronic hemodialysis patients. DefenCath has received FDA Fast Track designation and QIDP status for marketing exclusivity. However, the company also noted it received a Complete Response Letter from the FDA due to deficiencies at its manufacturing facility.
CorMedix Inc. (Nasdaq: CRMD) announced the acceptance of three abstracts for presentation at major conferences, focusing on catheter-related bloodstream infections (CRBSIs) in hemodialysis patients. Key highlights include:
- 29% of ~56,000 hemodialysis patients experienced CRBSI after central venous catheter (CVC) insertion.
- 54% of first CRBSIs occurred within three months of CVC insertion.
- Annual costs of $2.3 billion from CVC-related infections were estimated.
Dr. Matt David emphasized the importance of these findings in addressing the high incidence of CRBSIs and the potential of DefenCath to reduce these infections by approximately 71%.
CorMedix Inc. (Nasdaq: CRMD) has announced significant changes in its executive leadership. Khoso Baluch has retired as CEO effective October 4, 2021, alongside John Armstrong, EVP for Technical Operations. Matt David, the current EVP and CFO, has been appointed as interim CEO while the Board initiates a search for a permanent replacement. Baluch will assist as an advisor during the transition. The changes aim to maintain momentum in advancing CorMedix’s key product, DefenCath, which is under FDA review for its potential to prevent infections in hemodialysis patients.
CorMedix Inc. (Nasdaq: CRMD) announced delays in its DefenCath New Drug Application (NDA) due to issues at its third-party manufacturer. These issues are unrelated to the manufacturing of DefenCath, and the timeline for addressing deficiencies is currently uncertain. DefenCath is designed to prevent bloodstream infections in hemodialysis patients and has received Fast Track designation from the FDA. The company has committed to conducting a pediatric clinical study upon NDA approval, which could extend marketing exclusivity.
CorMedix Inc. (Nasdaq: CRMD) reported a net loss of $4.6 million for Q2 2021, versus $3.8 million in Q2 2020, attributed to higher personnel costs and lower tax benefits. Despite a 34% reduction in operating expenses to $5.9 million, SG&A expenses rose 4% to $3.4 million. Cash reserves are robust at $78.3 million, expected to cover operations through 2022. The company aims to address FDA deficiencies and plans to re-submit its DefenCath™ NDA by Q4 2021. CorMedix emphasizes its commitment to delivering an antimicrobial solution for hemodialysis patients.
CorMedix Inc. (Nasdaq: CRMD) will announce its second-quarter financial results on August 12, 2021, following market close, and hold a conference call at 4:30 PM ET. The company is focused on its lead product, DefenCath™, which aims to prevent infections in patients with central venous catheters during hemodialysis. DefenCath has received Fast Track designation and was granted a Qualified Infectious Disease Product status by the FDA, allowing for additional marketing exclusivity upon NDA approval. Investors may gain insights into upcoming clinical studies and financial outlook during the call.